Greek Alzheimer's Association and Related Disorders Report issue

Foundation Phase 2 Phase 4

Organization Overview

First Clinical Trial
2016
NCT03362996
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Greek Alzheimer's Association and Related Disorders

Active Ingredients

Drugs in Phase 4 Trials (2)

cannabidiol (Epidiolex) (1 trial)

homotaurine (1 trial)

Drugs in Phase 2 Trials (1)

olive (1 trial)

Drugs in Other Trials (1)

pomegranate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cognitive Dysfunction (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 4